The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Silexion Therapeutics Corp (SLXN) is seeking shareholder approval to add 500,000,000 authorized ordinary shares, increasing the authorized total from 15,900,000 to 515,900,000, subject to proportionate adjustment if the reverse-split proposal is also approved. Shareholders are also being asked to authorize a reverse split at a ratio from 1-for-15 to 1-for-25. The Board will select a ratio for shareholder approval and, if approved, may implement the split after the meeting. Both proposals are scheduled for a vote on October 19, 2026.
The company says the additional authorized shares would support Nasdaq shareholders’ equity compliance and clinical-program funding. Shareholders’ equity was approximately $3.177 million as of September 30, 2026, compared with $44,000 as of June 30, 2026; Nasdaq’s minimum is $2.5 million. The company received a deficiency notice after its closing bid price was below $1.00 for 30 consecutive business days, and a Nasdaq hearings panel is considering its compliance plan. Silexion says the authorization increase itself would not issue shares, but future issuances could dilute existing holders. 14,473,292 ordinary shares were outstanding as of September 30, 2026.
Silexion Therapeutics Corp (SLXN) announced that the first patient worldwide was successfully dosed in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The randomized, controlled, multinational, open-label study compares SIL204 plus standard-of-care chemotherapy with chemotherapy alone. It starts with an approximately 18-patient safety run-in, followed by an approximately 166-patient randomized cohort. The first treatment was administered at Tel Aviv Sourasky Medical Center in Israel.
Additional Israeli and German medical centers are progressing through site activation and are expected to join the trial in the coming months.
Silexion Therapeutics Corp. disclosed a warrant inducement in a supplement to a prospectus relating to 2,028,619 ordinary shares and 5,932,934 ordinary shares issuable upon exercise of investor, pre-funded and placement agent warrants. Holders agreed to exercise 3,216,928 Existing Warrants for ordinary shares at $0.2603 per share, reduced from $0.65. The Company expects approximately $0.84 million in gross proceeds before placement agent fees and other offering expenses; closing is expected on or about September 29, 2026, subject to customary closing conditions.
In exchange, the Company agreed to issue Series F and Series G warrants for up to an aggregate of 6,433,856 ordinary shares, with each series covering up to 3,216,928 shares, at $0.2603 per share. The new warrants are exercisable upon the effective date of an authorized ordinary-share increase following shareholder approval. The exercise price for all outstanding series E warrants covering 3,846,161 ordinary shares is also reduced to $0.2603 per share.
Silexion Therapeutics Corp (SLXN) entered an inducement agreement under which holders agreed to exercise for cash 3,216,928 existing Series E warrants at a reduced $0.2603 per share, down from $0.65. The company expects approximately $0.84 million in gross proceeds before placement-agent fees and other offering expenses; closing is expected on or about September 29, 2026, subject to customary conditions. In connection with closing, it is reducing the exercise price to $0.2603 for all outstanding Series E warrants covering 3,846,161 shares.
The agreement provides for new warrants to purchase up to 6,433,856 shares—3,216,928 Series F and 3,216,928 Series G—at $0.2603 per share, subject to shareholder approval for exercise. Series F expire five years and Series G 24 months after the later of the authorized share increase date and the resale registration statement’s effective date. Silexion agreed to issue H.C. Wainwright & Co., LLC, its exclusive placement agent, warrants for up to 225,185 shares at $0.3254 per share and pay it a 7.0% cash fee and a 1.0% management fee on gross proceeds from the existing-warrant exercises. Net proceeds are expected to fund general corporate purposes.
Silexion Therapeutics Corp (SLXN) reported translational-study findings that SIL204 used naturally occurring serum lipoproteins to enter human KRAS-driven cancer cells and produce dose-dependent knockdown of mutant KRAS expression in a carrier-free assay. Depleting serum lipids significantly reduced gene-knockdown efficiency (P < 0.001), while adding exogenous human LDL did not change potency compared with complete serum.
The company described physiological lipid levels as sufficient for cellular uptake without artificial carriers, providing mechanistic support for its systemic subcutaneous delivery strategy. The findings are preclinical; in vivo pharmacokinetic, cellular-uptake kinetics and tissue-biodistribution evaluations are underway. SIL204 is in a Phase 2/3 clinical program for locally advanced pancreatic cancer, with site initiation and patient screening ongoing.
Silexion Therapeutics Corp (SLXN) received a Nasdaq notice on September 25, 2026, stating that its ordinary shares’ closing bid price was below the $1.00 per share minimum for 30 consecutive business days.
Nasdaq staff said a hearings panel would consider the deficiency when deciding whether to enable Silexion to remain listed on the Nasdaq Capital Market. The notice has no immediate effect on the ordinary shares’ listing: they continue to trade under SLXN, and the listed warrants continue to trade as usual under SLXNW.
Silexion Therapeutics Corp (SLXN) is asking shareholders to approve two proposals: add 500,000,000 authorized ordinary shares, raising the authorized total from 15,900,000 to 515,900,000, and authorize a reverse split within a 1-for-15 to 1-for-25 range. The added authorized-share count would be reduced proportionately if the reverse split is approved. The Board recommends a “FOR” vote on both proposals.
As of September 24, 2026, 11,036,748 ordinary shares were outstanding. Shareholders’ equity was $44,000 as of June 30, 2026; adjusted for transactions through September 24, 2026, it was approximately $2.477 million, below Nasdaq’s $2.5 million Equity Standard. Silexion also reported a deficiency notice after its closing bid price was below $1.00 for 30 consecutive business days. The Board would select the split ratio and present it for shareholder approval; even if approved, the Board may choose not to implement it.
The authorized-share increase itself would not issue shares or dilute ownership, but future issuances could dilute existing holders. Silexion says the reverse split would generally preserve ownership percentages, apart from fractional-share adjustments; fractional shares would be rounded up or down, with no cash paid in lieu.
Silexion Therapeutics Corp (SLXN) reported that neither the authorized share capital increase nor the reverse share split proposal was approved at its reconvened extraordinary general meeting on September 23, 2026. Holders of 2,208,353 ordinary shares, approximately 36.8% of issued and outstanding ordinary shares, were present in person or by proxy. Under the company’s articles, after half an hour without the standard quorum, the shareholders then present constituted a quorum.
The authorized share capital increase proposal received 536,203 votes in favor (24.6%) and 1,645,147 against (75.4%), with 27,003 abstentions. The reverse share split proposal received 571,411 votes in favor (25.9%) and 1,636,939 against (74.1%), with 3 abstentions. The percentages exclude abstentions.
Silexion Therapeutics Corp (SLXN) is asking shareholders at a September 9, 2026 extraordinary general meeting to approve two capital-structure changes aimed at preserving its Nasdaq Capital Market listing and funding development of its RNAi oncology programs.
Proposal 1 would increase authorized share capital by 175,000,000 ordinary shares, from 15,900,000 to 190,900,000 shares (par value $0.135), an 1,100% increase in authorization. As of August 24, 2026, 5,755,872 ordinary shares were outstanding and significant portions of the remaining authorization are reserved for warrants, equity plans, an at-the-market program, and a promissory note to Moringa Sponsor, L.P.; an internal table shows the current plan usage would exceed the 15.9 million authorized shares. Management links this increase to maintaining compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of shareholders’ equity, and to providing capacity for future financings and business development.
Proposal 2 would authorize a reverse share split of all issued and authorized ordinary shares at a ratio between 1-for-7 and 1-for-15, with the exact ratio set by the board before the meeting. The split is intended to support compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement under Rule 5550(a)(2); Silexion has already completed 1-for-9, 1-for-15, and 1-for-10 reverse splits since 2024. The board states that percentage ownership and voting rights per holder will remain the same, except for rounding of fractional shares, and that authorized share count and par value will be adjusted proportionally.